What it is and how it works
hC2 is a first-in-class humanized antibody targeting the common gamma chain (gc) receptor. In autoimmune hair loss like alopecia areata, the immune system mistakenly floods the hair roots with destructive signals. hC2 acts like a localized filter, selectively modulating gc-dependent cytokine signaling to block these destructive signals so the immune cells never get the command to attack.
The Science
Unlike widely used JAK inhibitors that broadly quiet down the cells after they are already activated, hC2 selectively modulates gc-dependent cytokine signaling, offering a highly differentiated immunomodulatory approach. In the preclinical AA model, hC2 administration significantly reduced hair loss (p < 0.001) while lowering local T-cell infiltration and local inflammation.
Availability and Benefit
SinoMab is currently advancing its manufacturing optimization and toxicology studies, with plans to submit an Investigational New Drug (IND) application for alopecia areata as early as the fourth quarter of 2026. While hC2 is in preclinical stages, patients can benefit now by seeking out currently approved, targeted JAK inhibitors like deuruxolitinib (Leqselvi) to manage active scalp inflammation and protect viable hair follicles.